Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk

다국어 초록 (Multilingual Abstract)

Background and Objectives: Although recent lipid-lowering therapies are effective in reducing low density lipoprotein-cholesterol (LDL-C) levels, many patients treated with lipid-lowering agents do not achieve target LDL-C levels, especially in very high risk patients. The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Subjects and Methods: A total of 74 patients with very high risk were enrolled in the study. Very high risk patients were defined as patients that displayed established cardiovascular disease with multiple major risk factors, poorly controlled risk factors, multiple risk factors of the metabolic syndrome and acute co-ronary syndromes. Patients were randomized into two groups: ezetimibe/simvastatin 10/20 mg (n=36) and atorvastatin 20 mg (n=38). Follow-up lipid profile was obtained 6 weeks later. A target goal of LDL-C was defined as less than 70 mg/dL at follow-up. Results: Baseline clinical and laboratory data were similar between the two groups. Achieving a target LDL-C goal was observed in 41.7% of Group 1 and 44.7% of Group 2 at 6 weeks (p=0.82). Changes in other lipid profiles were not significantly different but the tolerability of the two groups was similar. Conclusion: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk.

참고문헌 (Reference)

1 Van Heek M, "omparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH60663" 129 : 1748-1754, 2000

2 Cannon CP, "Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes" 156 : 826-832, 2008

3 Collins R, "MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial" 361 : 2005-2016, 2003

4 Heart Protection Study Collaborative Group, "MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial" 360 : 23-33, 2002

5 Cannon CP, "Intensive versus mode-rate lipid lowering with statins after acute coronary syndromes" 350 : 1495-1504, 2004

6 Van Heek M, "In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461" 283 : 157-163, 1997

7 Grundy SM, "Implications of recent clini-cal trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines" 110 : 227-239, 2004

8 Goldberg RB, "Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study" 81 : 1579-1588, 2006

9 Davidson MH, "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia" 240 : 2125-2134, 2000

10 "Expert Panel on Detection, Evaluation, and Treatment of High Bl-ood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)" 285 : 2486-2497, 2001

11 Davidson MH, "Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia" 58 : 746-755, 2004

12 Goldberg AC, "Efficacy and safety of ezetimibe coadministered with si-mvastatin in patients with primary hypercholesterolemia: a randomiz-ed, double-blind, placebo-controlled trial" 79 : 620-629, 2004

13 Ballantyne CM, "Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia" 93 : 1487-1494, 2004

14 Baigent C, "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins" 366 : 1267-1278, 2005

15 Murphy SA, "Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocar-dial Infarction 22 trials)" 100 : 1047-1051, 2007

16 Ballantyne CM, "Dose-comparison study of the combination of ezetimibe and simvastatin versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study" 149 : 464-473, 2005

17 윤경호, "Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg" 대한심장학회 37 (37): 154-160, 2007

18 Kannel WB, "Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study" 90 : 85-91, 1979

19 "American Diabetes Association. Standards of medical care in diabetes: 2007" 30 (30): S4-41, 2007